医学
清除单元格
临床试验
肾细胞癌
肾透明细胞癌
癌
嫌色细胞
癌症研究
透明细胞癌
靶向治疗
肾癌
内科学
ARID1A型
液体活检
阿西替尼
分子病理学
病理
肿瘤科
作者
Philippe Barthélémy,Nathalie Rioux-Leclercq,Constance Thibault,Carolina Saldana,Delphine Borchiellini,Christine Chevreau,Isabelle Desmoulins,A. Gobert,Werner Hilgers,Ahmed Khalil,Nathalie Lemoine,Friederike Schlurmann-Constans,Sylvie Negrier
标识
DOI:10.1016/j.ctrv.2021.102191
摘要
Non-clear cell renal cell carcinomas (nccRCC) represent a highly heterogeneous group of kidney tumors, consisting of the following subtypes: papillary carcinomas, chromophobe renal cell carcinoma, so-called unclassified carcinomas or aggressive uncommon carcinomas such as Bellini carcinoma, renal cell carcinoma (RCC) with ALK rearrangement or fumarate hydratase-deficient RCC. Although non-clear cell cancers account for only 15 to 30% of renal tumors, they are often misclassified and accurate diagnosis continues to be an issue in clinical practice. Current therapeutic strategy of metastatic nccRCC is based primarily on guidelines established for clear cell tumors, the most common subtype, however this approach remains poorly defined. To date, published clinical trials for all histological nccRCC subtypes have been collectively characterized into one group, in contrast to clear cell RCC, and given the small numbers of cases, the interpretation of study results continues to be challenging. This review summarizes the available literature for each nccRCC subtype and highlights the lack of supportive evidence from prospective clinical trials and retrospective studies. Future trials should evaluate treatment approaches which focus on a specific histological subtype and progress in treating nccRCC will be contingent on understanding the unique biology of their individual histologies.
科研通智能强力驱动
Strongly Powered by AbleSci AI